stockrow
Sunday 8 November 2026
Export SCLX’s income statement to Excel — free account
Scilex Holding Company
SCLXHealthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024.
- Revenue
- −22.8%
- EPS
- −124.4%
- Free cash flow
- −203.8%
- Total debt
- +102.7%
Quarter to June 2026, against a year earlier
1.70
0.00
0.00%
Follow SCLX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| 160.27% | 180.29% | 199.06% | 192.22% | ||
| (265.83%) | (225.26%) | (175.78%) | (199.75%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
96.78% | 94.01% | 93.23% | 109.97% | |
Average Days of Receivables |
74.36 | 114.76 | 183.92 | 107.99 | |
Free Cash Flow per Share |
(2.59) | (0.48) | 0.33 | 2.05 | |
Free Cash Flow |
(17.82) | (3.30) | 3.65 | 23.82 | |
Capital Expenditures |
(0.73) | — | (0.16) | — | |
| Other line items | |||||
Cash ROIC |
7.78% | 1.94% | (3.11%) | (17.89%) | |
Accounts Receivable Turnover |
2.72 | 3.18 | 1.45 | 1.85 | |
Accounts Payable Turnover |
0.16 | 0.17 | 0.15 | 0.23 | |
Inventory Turnover |
4.21 | 3.62 | 2.93 | 7.27 | |
Average Days of Payables |
3,140.91 | 2,713.80 | 2,970.76 | 1,939.66 | |
Days of Inventory on Hand |
108.23 | 121.08 | 164.92 | 31.16 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
58.89% | 63.39% | 68.46% | 36.48% | |
Selling, General and Administrative Expense of Revenue |
879.45% | 796.93% | 882.17% | 674.26% | |
Share Based Compensation of Revenue |
54.69% | 46.68% | 51.21% | 36.31% | |
Interest Coverage |
(20.45) | — | (24.82) | (31.93) | |
Operating CF/Net income |
0.04 | 0.01 | (0.01) | (0.06) | |
Depreciation/Fixed assets |
6.59 | 6.08 | 5.76 | 6.06 | |
Capex/Depreciation |
(0.01) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
4.59 | 4.91 | 2.74 | 3.48 | |
Operating CF per Share |
(2.48) | (0.48) | 0.35 | 2.05 | |
Capex per Share |
(0.11) | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.01 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026